News Archive

WASHINGTON, May 9, 2024 /PRNewswire/ — Danaher Corporation (NYSE: DHR), a global science and technology innovator (“Danaher”), today launched a collaboration with Johns Hopkins University aiming to develop new methods for diagnosing mild TBI. As part of the Danaher Beacons program, researchers at Johns Hopkins University will leverage technology from Beckman Coulter Diagnostics, a Danaher subsidiary and leader in clinical diagnostics, to potentially establish correlations between a new biomarker panel and clinical outcomes.

Julie Sawyer Montgomery, Vice President and Group Executive, Danaher Diagnostics, said: “Our latest in vitro diagnostics innovations are improving the detection of specific biomarkers found in blood when brain cells are damaged. We are thrilled to partner with Johns Hopkins with the goal of leveraging these solutions to develop tests for earlier and more precise diagnosis of mild TBI, which could ultimately lead to improved treatment outcomes and faster recovery for patients.”

COLUMBIA, Md., May 9, 2024 — Welldoc^®, a leading digital health company specializing in cardiometabolic health, today announced that it has been selected as winner of the “Best Overall Digital Health Company” award for the second consecutive year in the 8th annual MedTech Breakthrough Awards. The awards program is conducted by MedTech Breakthrough, an independent market intelligence organization that recognizes the top companies, technologies and products in the global digital health and medical technology market. This is the third year that MedTech Breakthrough has recognized Welldoc for its leadership and innovation in the digital health industry.  

The AI-powered Welldoc platform offers flexible, multi-condition digital coaching across diabetes, weight management with GLP-1 support, hypertension, heart failure, and prediabetes, with integrated mental wellbeing and sleep guidance. Through personalized, real-time and actionable insights, the platform empowers individuals to better self-manage their health and provides care teams with critical data to inform clinical decision-making. 

COLUMBIA, MD (May 8, 2024) – Maryland’s leading edge in stem cell research was on full display at the Maryland Stem Cell and Regenerative Medicine Technology Showcase (“Showcase”) on April 25, 2024. This event, hosted as a collaborative effort between Maryland Stem Cell Research Fund (MSCRF) and the Maryland Department of Commerce, served as a platform to highlight groundbreaking advancements in stem cell and regenerative medicine from MSCRF portfolio members.

“This is an exciting time in the regenerative medicine space and the Maryland Stem Cell Research Fund is honored to support the innovations in stem cell therapy taking place in Maryland,” said MSCRF executive director, Ruchika Nijhara, PhD. “Maryland is home to pivotal and innovative stem cell research, and we are pleased to partner with the Department of Commerce to bring the regenerative medicine community together to share their cutting-edge research in this growing field.” 

Agreement allows ImmunoACT to develop and commercialize a novel TriCAR-T cell therapy for leukemia and lymphoma designed to decrease lapses seen in current single CAR-T cell therapies and improve outcomes

GAITHERSBURG, Md. and MUMBAI, India, May 7, 2024 /PRNewswire/ — Caring Cross, a 501(c)(3) non-profit dedicated to accelerating the development of advanced medicines and enabling access to cures for all patients, everywhere, and ImmunoAdoptive Cell Therapy (ImmunoACT), a Mumbai, India-based pioneering research and cell and gene therapy development company, announced an agreement to develop and commercialize a multi-targeted chimeric antigen receptor T-cell immunotherapy for leukemia and lymphoma. The TriCAR-T immunotherapy is designed to address relapse that can occur when patients with Leukemia or Lymphoma are treated with a single targeting anti-CD19 CAR T-cell product. Under the terms of the agreement, Caring Cross will provide a TriCAR-T cell immunotherapy for clinical development, manufacturing, and commercialization at ImmunoACT’s facilities in India.

The NIH Entrepreneurship Bootcamp is designed to equip life science investigators and nascent companies with specialized innovation and entrepreneurship training. The course requires no prior experience and uses a life science-focused customer discovery process to assess customer and stakeholder needs, and teaches participants to develop stronger business models, market strategies, and commercialization plans in advance of their initial SBIR/STTR application.

The Bootcamp places teams on a path to take advantage of other NIH innovation programs, particularly the I-Corps and SBIR programs. Critically, this course will improve the commercialization potential of a project no matter what direction teams ultimately pursue. The program is differentiated from I-Corps@NIH as it targets teams who have not yet been awarded an SBIR or STTR for their technical innovation and who may not yet have formed a company. More information is available through NOT-OD-24-103.

Join us for Meet With…Johnson & Johnson’s Immunology Team at JLABS @ Washington, DC on May 21.

During Digestive Disease Week 2024, our Johnson & Johnson Immunology Team will present our strategic priorities in the space as part of our search for promising scientific innovations in the following areas: differentiated MOAs with potential for gut barrier restoration, patient stratification or use in combination regimes, and orals for clinically validated targets.

J

WASHINGTON–(BUSINESS WIRE)–Nanochon, a Washington, DC-based orthopedic device biotech company has raised $4 million in its series seed prime fundraising round.

welldoc® recently presented a new clinical research paper at the 14th annual Conference on Health IT and Analytics (CHITA) in Washington, D.C. This research focuses on the latest advancements in artificial intelligence and weight management, areas of significant interest across the healthcare industry.

Hosted by the Center for Digital Health and Artificial Intelligence (CDHAI) at the Johns Hopkins Carey School of Business, CHITA explores innovative developments in the design, implementation, and management of health information technology and analytics.

Welldoc’s presentation, authored by Abhi Kumbara, Anand Iyer, and Mansur Shomali in collaboration with their colleagues from Johns Hopkins CDHAI, is now available on their website.

BETHESDA, Md., May 06, 2024 (GLOBE NEWSWIRE) — AsclepiX Therapeutics, Inc., a clinical-stage biopharmaceutical company leveraging computational biology from Johns Hopkins to identify and develop peptides for improved treatments of retinal diseases, today announced the completion of enrollment into the DISCOVER trial (NCT05859776). Fifteen patients have completed enrollment in the trial for AXT107 (gersizangitide). The objectives of the trial are to evaluate the safety and tolerability of three dose strengths of AXT107 [125 µg (n=3), 250 µg (n=3), and 500 µg (n=9)] and to determine the bioactivity and duration of action when injected suprachoroidally. Secondary endpoints will include efficacy as assessed by central subfield thickness (CST) and best-corrected visual acuity (BCVA). Following a single injection of AXT107, to date, no patient has shown any remarkable safety findings.

ROCKVILLE, Md.–(BUSINESS WIRE)–GlycoMimetics, Inc. (Nasdaq: GLYC), a late clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers and inflammatory diseases, today announced topline results from its Phase 3 global pivotal study of uproleselan in 388 patients with R/R AML. In the study, uproleselan combined with chemotherapy did not achieve a statistically significant improvement in overall survival in the intent to treat population versus chemotherapy alone.